CT-guided radiofrequency ablation for lung cancer：a retrospective analysis of 35 cases
10.3969/j.issn.1008-794X.2015.06.016
- VernacularTitle:CT引导下射频消融治疗33例肺癌的回顾性分析
- Author:
Jun LUO
;
Guoliang SHAO
;
Jiaping ZHENG
;
Yutang CHEN
;
Zheng YAO
;
Hui ZENG
;
Weiyuan HAO
- Publication Type:Journal Article
- Keywords:
lung cancer;
radiofrequency ablation;
progression-free survival
- From:
Journal of Interventional Radiology
2015;(6):530-533
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of CT-guided radiofrequency ablation (RFA) in treating lung tumors. Methods A total of 33 patients with lung cancer (35 lesions in total), who were admitted to authors’ hospital during the period from May 2007 to August 2013 to receive treatment, were enrolled in this study. RFA was carried out in all patients. After RFA the patients were followed up regularly (once every 3 months) to evaluate the therapeutic efficacy and the adverse reaction. The deadline for the following-up was November 2013, or to the time when tumor progression occurred. Results Of the total 34 lesions in 32 patients who had received RFA and had complete follow-up data, the one-year local control rate was 85.3%. The average one-year progression-free survival rate was 75.0%, among them 15 cases with primary lung cancer had a mean one-year progression-free survival rate of 80.0% and 17 cases with metastatic lung cancer had a mean one-year progression-free survival rate of 70.6%. The overall median progression-free survival (PFS) was(18.0±1.3) months. No obvious correlation existed between PFS and age, sex, tumor size, pathological type, clinical stage (P<0.05). The main adverse reactions of RFA were pain, hydrothorax and pneumothorax; no serious life-threatening complications occurred. Conclusion RFA is a safe, effective and minimally-invasive treatment for lung cancer, regardless of early stage or late stage of the tumor.
